ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Actinium Ac 225 GPC3-targeted Peptide RYZ801

Its studies are mostly in Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.

Furthest: phase 2, since Nov 5, 20241 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 2since Nov 5, 2024Nov 5, 2024Jun 2030phase 2 · NCT06726161
  • Named in Bristol-Myers Squibb’s own pipeline as RYZ801, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2024First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06726161 · 590 planned · United States

Ahead

  1. Jun 2030Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06726161

TargetBeta

“A radioconjugate composed of a glypican-3 (GPC3; GPC-3)-binding peptide conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity against GPC3-expressing tumor cells. Upon administration of actinium Ac 225 GPC3-targeted peptide RYZ801, the GPC3-binding …”NCIt, read by Claude

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
codrituzumabHoffmann-La Rochephase 23
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 22
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 11
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 11
ACE723ruleacepodia-biotech-incphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06726161Carcinoma, Hepatocellular · United States2RecruitingJun 2030590

How it is read

Names in the registry

  • “RYZ801”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.